BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio

Reuters12-18 18:33

Dec 18 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:

SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONS
SAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTION

Source text

Further company coverage: 600196.SS

(Reporting by Beijing Newsroom)

((Ethan.Wang@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592972480?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592972480","market":"fut","top_or_hot":-1,"title":"BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONS</p></li><li><p>SAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTION</p></li></ul><p>Source text</p><p>Further company coverage: <span>600196.SS</span></p><p> (Reporting by Beijing Newsroom)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 18:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONS</p></li><li><p>SAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTION</p></li></ul><p>Source text</p><p>Further company coverage: <span>600196.SS</span></p><p> (Reporting by Beijing Newsroom)</p><p> ((Ethan.Wang@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0QP:1","article_id":"2592972480","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592972480","pubTimestamp":1766053985,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio Dec 18  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONSSAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTIONSource textFurther company coverage: 600196.SS  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","BK0196":"行业龙头","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"简介-复星医药旗下子公司与Clavis Bio签署共同开发、许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9},"content_text":"BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio Dec 18 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONSSAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTIONSource textFurther company coverage: 600196.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592972480","isCrawlerRequest":true}